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ABSTRACT
Though outcomes for pediatric Burkitt lymphoma (BL) have improved significantly 
in recent decades with intensive multi-agent chemotherapy and the addition of 
rituximab, chemotherapy resistance remains a significant impediment to cure 
following relapse. Activation of the PI3K/AKT pathway has been implicated in Burkitt 
lymphomagenesis and increased PI3K/AKT activation has been associated with worse 
outcomes in adults with aggressive B-cell non-Hodgkin lymphoma (B-NHL). Inhibitors 
of the PI3K/AKT pathway have been approved for the treatment of refractory indolent 
B-NHL and continue to be investigated for treatment of aggressive B-NHLs. We 
investigated the activation of the PI3K/AKT pathway in a cell line model of resistant 
BL and the ability to target this pathway with small molecule inhibitors in BL cell 
lines. We found that cell lines resistant to rituximab and chemotherapy exhibited 
increased activation of PI3K/AKT and that inhibition of AKT or PI3K results in in 
vitro anti-lymphoma activity. To investigate the role of PI3K/AKT activation on the 
efficacy of cytotoxic chemotherapy, we exposed cells to inhibitors in combination 
with chemotherapy and noted a synergistic increase in response to chemotherapy. 
Overall these findings highlight the role of PI3K/AKT in chemotherapy resistance in 
BL cells and may represent a tractable therapeutic target.
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INTRODUCTION
Burkitt lymphoma (BL) is an aggressive form of 
B-cell non-Hodgkin lymphoma (NHL) and is the most 
common type of NHL in children. With intense, multi-
agent chemotherapy regimens, survival rates for childhood 
BL have improved significantly in recent decades. 
Currently, greater than 90% of children diagnosed with 
BL are cured of their disease [1, 2]. While highly curable, 
the therapy is quite toxic with high rates of acute toxicity 
including mucositis and infections. Approximately 2% of 
children with BL die from toxic complications of therapy 
[3–5]. In the small percentage of children who develop 
relapsed or refractory disease, the prognosis is much 
grimmer with long term survival achieved in only 20–30% 
of children following further intensified therapy, generally 
including either autologous or allogeneic hematopoietic 
stem cell transplant, necessitating the development 
of novel therapeutic approaches in an attempt to both 
decrease toxicity in up-front therapy and prolong survival 
in relapsed/refractory disease [6–9].
Recent publications have reported on genomic 
alterations observed in BL which contribute to 
lymphomagenesis. Several recurrent abnormalities have 
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been described by our group and others [10–12]. Schmitz 
et al identified genomic abnormalities in sporadic BL cases 
and cell lines [13]. Compared to tumor cells from germinal 
center B-cell (GCB) derived diffuse large B-cell lymphoma 
(DLBCL), BL tumors harbor recurrent mutations that were 
distinct from those seen in GCB DLBCL. Along with 
the expected mutation of the C-MYC proto-oncogene, 
additional recurrent mutations were observed in in the gene 
encoding TCF3 and that of its negative regulator ID3 with 
up to 70% of tumors bearing mutations in one or both of 
the genes suggesting TCF3 may play a vital role in BL 
lymphomagenesis. This was further supported by the lethal 
effects of TCF3 knockdown or ID3 wildtype overexpression 
in BL cell lines. TCF3 was noted to upregulate components 
of the B-cell receptor (BCR) pathway leading to activation 
of the phosphatidylinositol-3-kinase (PI3K) pathway 
through “tonic” non-NF-kB dependent BCR signaling, 
rather than the NF-kB dependent chronic active BCR 
signaling seen in activated B-cell like (ABC) DLBCL, 
potentially through its effects on the phosphatase SHP-1 
which inhibits BCR signaling. Additional data supporting 
the relevance of the PI3K pathway to BL lymphomagenesis 
was reported in a recently developed transgenic mouse 
model and in a proteomic analysis reported by our group 
[14, 15]. In this model, concurrent activation of both 
c-Myc and PI3K was noted to lead to lymphoid tumors that 
morphologically and genetically appear BL-like suggesting 
the coordination of overexpression of Myc and activation of 
PI3K may contribute to development of BL. 
Overexpression of Myc may further contribute to the 
activation of PI3K through the Myc dependent induction of 
microRNAs (miRs) associated with PI3K activation through 
their inhibitory effect on PTEN, in particular the miR17-
92 cluster [16, 17]. Increased expression of Myc-induced 
miRs has been linked to increased relapse risk in childhood 
BL. A genome wide copy number analysis of childhood 
BL samples identified a recurrent gain in the region of 
13q31, which incorporates the MIR17HG locus [18]. These 
samples had higher expression of miR-17 and tended toward 
early relapse. These findings were further validated by a 
second report associating increased expression of miR-17 
with shorter overall survival (OS) [19]. 
With the apparent importance of c-Myc and PI3K 
coordination in BL lymphomagenesis, we investigated 
the activity of inhibitors of the PI3K/Akt/mTOR pathway 
in BL cell lines. Numerous inhibitors of this pathway 
are in clinical development including both narrowly and 
broadly focused inhibitors in addition to dual inhibitors 
of both PI3K and mTOR. The more targeted inhibitor 
of the delta isoform of PI3K, idelalisib, has already 
gained regulatory approval for the treatment of relapsed 
chronic lymphocytic leukemia (CLL), small lymphocytic 
lymphoma (SLL) and follicular lymphoma (FL). In our 
current contribution, inhibition of the PI3K/Akt/mTOR 
pathway was investigated in a panel of BL cell lines 
including cell lines that exhibit a high degree of resistance 
to both chemotherapy and anti-CD20 immunotherapy.
RESULTS
With reported evidence of increased Akt activation 
having a potential impact on survival in B-cell NHL 
[20–23], we initially characterized the Akt activation in 
our sensitive and resistant Raji cell lines. On Western blot 
analysis of p-Akt expression, rituximab-chemotherapy 
sensitive Raji cells exhibited lower p-Akt expression 
when compared to the rituximab-chemotherapy resistant 
Raji 2R and Raji 4RH cell lines (Figure 1A). Similar 
findings were observed using phospho-flow cytometry, 
where an approximately 2 fold increase in p-Akt was 
observed in the resistant Raji cell lines (Figure 1B and 
Supplementary Figure 1). In order to further evaluate the 
activation of Akt in these cell lines, the phosphorylation 
status of downstream targets of Akt was also determined 
using Western blotting (Supplementary Figure 2). In the 
resistant cell lines, multiple targets of Akt demonstrated 
a pattern of increased phosphorylation in the resistant 
cell lines (Figure 1C). Additionally, in a previously 
reported phosphoproteomic analysis of parental Raji 
cells compared to rituximab-chemotherapy resistant Raji 
4RH cells, the B-cell receptor pathway was one of the top 
pathways with significant differential phosphorylation 
including differential phosphorylation of several proteins 
both up and downstream of PI3K and Akt associated with 
PI3K/Akt pathway activation (Figure 1D). These findings 
indicated a possible role of increased activation of the 
PI3K/Akt/mTOR pathway in the chemotherapy resistance 
observed in our resistant BL cells suggesting that targeting 
this pathway may be therapeutically relevant in BL. 
With Akt being central to activity of the PI3K/Akt/
mTOR pathway, we initially investigated the effect of 
direct Akt inhibition with the pan-Akt inhibitor MK-2206. 
Burkitt cell lines were exposed to MK-2206 over a range 
of concentrations and durations. Direct inhibition of Akt 
by MK-2206 resulted in a decrease in cellular proliferation 
exhibited in AlamarBlue assays of cell viability compared 
to control (Figure 2). While a decrease in cell proliferation 
was observed, determination of apoptosis induction 
by western blot for cleaved PARP indicated that Akt 
inhibition by MK-2206 was not leading to significant 
apoptosis induction as a single agent in any of the Raji 
cell lines; though a modest increase in PARP cleavage 
was noted in Ramos cells indicating that this was likely a 
primarily anti-proliferative effect (Figure 3A). 
In order to investigate the hypothesis that 
PI3K/AKT/mTOR pathway activation contributes to 
chemotherapy resistance, we investigated targeting 
AKT either via siRNA knockdown or with MK-2206 in 
combination with chemotherapeutic agents (Figure 3). 
Following AKT knockdown, cells were resuspended 
in fresh medium and cell proliferation and viability 
were determined after 72 hours using Trypan blue. A 
decrease in cell proliferation and viability was noted in 
knockdown cells as compared to cells transfected with 
a control scramble siRNA. This was particularly noted 
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in the Raji 4RH cells with a decreased number of cells 
(scramble vs siRNA: 0.41 × 106 vs 0.12 × 106 cells/mL) 
and viability (82% vs 62%). Following demonstration of 
Akt knockdown by Western blot, an Alamar Blue assay 
was performed after 48 h of incubation with doxorubicin. 
In Raji Akt KD cells, a modest increase in response to 
doxorubicin was noted with a decrease in viability of 
KD cells compared to controls (27% vs 19%, p < 0.03) 
(Figure 3A). When BL cell lines were exposed to both 
MK-2206 and chemotherapy, significant increases in 
chemotherapy activity were noted. In particular, the 
combination of MK-2206 with doxorubicin (CI values 
0.4–0.7) (Figure 3C) or dexamethasone (CI values 0.3–0.8) 
(Figure 3D) resulted in significant synergistic reductions in 
viable cells in AlamarBlue assays when compared to either 
single agent exposure after normalization to vehicle treated 
control, as determined using the Chou-Talalay method. 
Additionally, while single agent MK2206 exposure did not 
result in significant induction of apoptosis as measured by 
western blot for PARP cleavage, a synergistic increase in 
cleaved PARP was noted in combinations of MK-2206 and 
doxorubicin in both Raji and Ramos cell lines (Figure 3B). 
In the resistant Raji 4RH cells, however, there was still no 
significant indication of apoptosis induction. This is likely 
related to the highly impaired apoptotic machinery in these 
resistant cell lines, also previously described. 
To further investigate the role of PI3K/Akt/
mTOR pathway inhibition in BL, additional experiments 
were performed with the PI3K-delta isoform specific 
inhibitor idelalisib, which is already FDA approved for 
relapsed/refractory CLL/SLL and FL. Similar to MK-
2206, a decrease in BL cell viability was noted with 
increasing concentrations of idelalisib while Idelalisib 
exposure also resulted in dose-dependent cell cycle 
arrest leading to a significant accumulation of cells 
primarily in G1, though with significant G2/M arrest 
also noted in resistant Raji 4RH cells (Figure 4C and 
Supplementary Figure 3). The concentrations required 
to achieve activity in the BL cell lines tested was well 
into the  μM range with IC50 concentrations ranging 
from 50–300 μM after a 48 h exposure (Figure 4A). At 
concentrations at or exceeding the IC50 concentration, 
idelalisib did result in induction of apoptosis in all 
cell lines, though to a significantly lesser degree in the 
resistant Raji 4RH cells (Figure 4B and Supplementary 
Figure 4). Inhibition of PI3K-delta with idelalisib inhibited 
downstream pathway activation as exhibited by decreases 
in the phosphorylation of downstream targets including 
pS6 and pGSK3B by western blotting (Figure 4D). 
Though idelalisib required high concentrations to 
demonstrate single agent anti-proliferative activity, 
lower concentrations of idelalisib when combined with 
Figure 1: Chemotherapy resistant BL cell lines exhibit an increase in Akt activation. Raji 2R and Raji 4RH cell lines derived 
from the BL Raji cell line demonstrate an increase in Akt phosphorylation by (A) Western blot and (B) phosphoflowcytometry indicating 
increased activation of the PI3K/Akt pathway. (C) Proteins up and downstream from AKT in the B-cell receptor and PI3K/AKT pathways 
are differentially phosphorylated in Raji 2R and Raji 4RH cells compared to parental Raji cells on Western blotting. (D) Phosphoproteomic 
analysis identified the B cell receptor signaling pathway as one of the top differentially phosphorylated pathways in Raji 4RH cells with 
several targets of AKT exhibiting increased phosphorylation. Error bars represent 95% confidence intervals. (^P-value < 0.03).
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Figure 2: Inhibition of Akt by the inhibitor MK-2206 leads to a decrease in cellular viability in a panel of BL cell lines. 
(A) The BL cell lines Raji, Raji 2R, Raji 4RH, Ramos and Daudi were exposed to escalating concentrations of MK2206 for 48 hours and 
exhibited a dose dependent decrease in viable cells. (B) IC50 concentrations at 48 hours. Error bars represent 95% confidence intervals.
Figure 3: Knockdown of AKT or inhibition of AKT by MK2206 leads to an increase in response to cytotoxic 
chemotherapy. (A) Akt knockdown by siRNA led to a decrease in Raji cell viability following 48 hour exposure to doxorubicin. (B) BL 
cell lines were exposed to MK2206 alone or in combination with doxorubicin for 48 hours and apoptosis was measured by Western blot 
for cleaved PARP. Raji and Ramos cells exhibited little apoptosis following exposure to MK2206 alone however a synergistic increase in 
PARP cleavage was noted with the combination treatment. In vitro exposure to MK2206 and (C) doxorubicin or (D) dexamethasone leads 
to a synergistic decrease in cell viability in BL cell lines. Error bars represent 95% confidence intervals. (^p < 0.05. M = MK2206, D = 
Doxorubicin, Dex = Dexamethasone).
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dexamethasone led to a synergistic induction of apoptosis, 
in particular in the relatively more sensitive Ramos and 
Daudi cell lines (Figure 5A and Supplementary Figure 5). 
Western blots also demonstrated a synergistic induction 
of PARP cleavage in Raji cells treated with idelalisib and 
dexamethasone (Figure 5B). This correlated with changes 
in expression of Bcl-2 family proteins including an increase 
in pro-apoptotic Bax and Bak and a decrease in anti-
apoptotic MCL-1 leading to an overall more pro-apoptotic 
pattern of Bcl-2 family protein expression (Figure 5C). 
DISCUSSION
BL is an aggressive form of B-NHL that is 
highly curable with intensive multi-agent chemoi-
mmunotherapeutic regimens [24–26]. Our group and 
others have reported that recurrent genetic abnormalities 
have been observed in children with BL including the 
critical importance of the PI3K/Akt/mTOR pathway 
in Burkitt lymphomagenesis [10, 12–14, 18, 19, 27]. 
Inhibitors of this pathway continue to be investigated in 
adult lymphoma with most success noted in more indolent 
lymphoma sub-types. Activity of idelalisib in adults with 
DLBCL has been very limited. 
In our preclinical testing, we demonstrated that, in 
our cell line model of resistant BL, the PI3K/AKT/mTOR 
pathway appears to exhibit increased activation. Targeting 
either AKT or PI3K with pharmacological inhibitors led to 
primarily an anti-proliferative effect in a panel of Burkitt cell 
lines with the majority of activity noted at concentrations 
in the high  μM range. In general these concentrations 
exceed the peak plasma concentrations noted in phase 
1 pharmacokinetic studies of these agents in humans 
[28, 29]. This limited in vitro activity at biologically relevant 
concentrations may relate to the lack of activity noted in 
single agent trials of idelalisib in aggressive B-cell NHLs. 
However, at concentrations below those leading to 
single agent activity, there was noted to be an increase in 
apoptosis induction in response to chemotherapy exposure 
in combination with inhibition of AKT or PI3K. In a report 
Figure 4: Inhibition of PI3K-delta isoform by idelalisib leads to decreased proliferation and induction of apoptosis in 
BL cell lines. (A) In vitro exposure to idelalisib for 24 or 48 hours leads to a dose- and time-dependent decrease in BL cell viability and 
(B) induction of apoptosis after 48 hours of exposure. (C) Decreased proliferation is associated with an arrest in G1 or G2/M phase of the 
cell cycle after a 48 hour exposure to idelalisib. (D) Idelalisib exposure leads to decreased phosphorylation of downstream targets. Error 
bars represent 95% confidence intervals. (*p < 0.01, ^p < 0.05).
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from the Bonavida laboratory, the PI3K/Akt pathway was 
previously noted to be involved in chemosensitization 
observed following exposure of BL cell lines to the anti-
CD20 monoclonal antibody rituximab [30]. While this 
previous report implicated a decrease in the anti-apoptotic 
Bcl-xL protein, we did not observe such a decrease 
following PI3K inhibition with idelalisib, though we did 
note changes in expression of other Bcl-2 family proteins 
including the pro-apoptotic Bax and Bak proteins likely 
leading to a similar alteration in apoptotic potential 
following PI3K inhibitor exposure [31]. The possible 
contribution of increased AKT activation to resistance to 
rituximab in DLBCL has also been suggested [32]. The 
interaction of BCL-2 family regulators of apoptosis and 
activity of the PI3K/AKT/mTOR pathway has been further 
highlighted by the synergistic activity of BH3 mimetic 
agents in combination with inhibition of the PI3K/
AKT/mTOR pathway with findings of altered MCL-1 
and BAX expression following inhibition of PI3K/AKT/
mTOR, similar to our results reported here, associated 
with increased activity of the BCL-2 inhibitor ABT-199 
[31, 33, 34]. Additionally, the PI3K/Akt/mTOR pathway 
has been reported to play a central role in the activity of 
a variety of targeted therapeutic agents under pre-clinical 
investigation in aggressive B-cell NHL, in many cases 
through alterations in BCL-2 family protein expression 
[35–38].
While single agent inhibition of PI3K has 
demonstrated promise in targeting B-NHL, the 
investigation of agents targeting the PI3K/AKT/mTOR 
pathway with enhanced activity has also led to the 
development of numerous inhibitors more broadly 
targeting PI3K (compared to the delta isoform specific 
idelalisib) or targeting both up- and down-stream targets 
in the pathway, such as through dual targeting inhibitors of 
PI3K and mTOR. Such agents have exhibited pre-clinical 
and clinical activity expanding the repertoire of agents 
targeting this pathway [39–43].
Though PI3K inhibitors have led to limited single 
agent activity in aggressive adult B-cell lymphomas, 
considering the data suggesting synergistic activity of 
PI3K/AKT/mTOR inhibition, a more rational application 
may be in the setting of combination therapy along 
with cytotoxic chemotherapy or other targeted agents. 
A potential area of concern in regards to the use of 
agents targeting this pathway is an apparent high rate of 
Figure 5: Exposure to idelalisib increases induction of apoptosis in response to cytotoxic chemotherapy. (A) BL cells 
exposed to idelalisib and dexamethasone for 48 hours exhibit synergistic induction of apoptosis as measured by flow cytometry for 
Annexin V and propidium iodide staining in BL Ramos and Daudi cells, but no apoptosis induction in Raji or Raji 4RH cells in vitro. 
(B) PI3K inhibition by idelalisib leads to synergistic induction of PARP cleavage when combined with dexamethasone in Raji cells and 
when combined with dexamethasone or doxorubicin in Daudi cells. (C) Idelalisib exposure leads to altered expression of Bcl-2 family 
regulators of apoptosis. (Dex = Dexamethasone, Dox = Doxorubicin).
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toxicities, including potentially serious gastrointestinal, 
hepatic and pulmonary toxicities, that have been observed 
in adult patients being treated with idelalisib or the 
Bruton’s tyrosine kinase inhibitor ibrutinib, in particular 
when utilized in combination with other therapeutic 
agents [44, 45]. This may impair the ability to combine 
these agents with the types of chemotherapy agents 
typically used in treating BL. Additionally, despite the 
dismal prognosis for such patients, the rarity of childhood 
relapsed/refractory BL along with the sheer number of 
available agents currently under investigation in adults 
(including numerous agents targeting the PI3K/Akt/mTOR 
pathway) complicates the choice of which agents to pursue 
clinically, making the establishment of biological rationale 
critical to future clinical investigation of novel therapies in 
pediatric B-NHL.
In summary, targeting PI3K appears to have 
biological relevance in BL and in vitro targeting of the 
PI3K/Akt/mTOR pathway in models of BL exhibits 
promising pre-clinical activity validating further pursuit 
of novel therapeutic agents targeting this pathway in 
BL. Though initial clinical trials of idelalisib in adults 
with DLBCL have been less promising, the activity of 
narrow versus broad inhibition of PI3K, further upstream 
inhibition with inhibitors of the B-cell receptor or dual 
inhibition of both up and downstream targets within the 
pathway also continue to be investigated and may hold 
additional promise of clinical efficacy, while observed 
toxicity continues to be a potential limiting factor to 
incorporation of these agents to the intense chemotherapy 
regimens generally used in treating aggressive childhood 
B-NHLs and needs to be further characterized.
MATERIALS AND METHODS
Cell lines and culture
BL cell lines were used for the experiments 
including Raji, Ramos and Daudi and were purchased 
from American Type Culture Collection (ATCC, 
Manassas, VA, USA). Rituximab resistant cell lines Raji 
2R and Raji 4RH were created and characterized from 
parental Raji cells as previously described [46, 47]. All 
cell lines were maintained in RPMI 1640 with Glutamax-1 
(Invitrogen, Karlsruhe, Germany) supplemented with 
10% heat-inactivated fetal bovine serum (FBS), HEPES 
(5 mmol/l), penicillin and streptomycin at 100 IU/ml and 
sodium pyruvate 1 mmol/l. 
Reagents and antibodies
The AKT inhibitor (MK-2206) and the PI3K-
delta inhibitor (idelalisib) were purchased from Selleck 
Chemicals (Houston, TX, USA). Cisplatin was purchased 
from American Pharmaceutical Partners (Schaumburg, 
IL, USA). Doxorubicin was obtained from Bedford Labs 
(Bedford, OH, USA) and dexamethasone was provided by 
the Roswell Park Cancer Institute (RPCI) Pharmacy. 
Primary mouse anti-human antibodies raised 
against BAK, BAX, BCL-XL, MCL-1, PARP, AKT, 
p-AKT, GSK3B, p-GSK3B, S6, p-S6, PDK1, p-PDK1, 
p27, p21, BAD, p-BAD, 4-EBP1, p-4-EBP1 and actin 
were purchased from Cell Signaling Technologies 
(Danvers, MA, USA). Alkaline phosphatase (AP) 
or horseradish peroxidase (HRP) conjugated anti-
mouse secondary antibodies were purchased from 
Jackson ImmunoResearch (West Grove, PA, USA). 
Ficoll-Hypaque was purchased from Sigma-Aldrich 
Inc. (St. Louis, MO, USA). Sodium chromate51 (51Cr) 
(Perkin-Elmer Life Inc., Boston MA) was utilized in 
immunological assays assessing antibody-dependent 
cellular cytotoxicity (ADCC) and complement mediated 
cytotoxicity (CMC). Triton X-100, trypan blue and 
histopaque-1077 were obtained from Sigma-Aldrich Inc. 
(St Louis, MO). Cell Titer-Glo Luminescent Viability 
Assay reagent was purchased from Promega (Madison, 
WI, USA). PrestoBlue cell proliferation assay reagent 
was purchased from (Invitrogen, Grand Island, NY, 
USA). AKT siRNA (ON-TARGET plus Smart Pool 
siRNA) was purchased from Dharmacon (Lafayette, 
CO, USA). 
Transient siRNA AKT knockdown
A transient AKT siRNA knockdown was performed 
in Raji and Raji 4RH cells. Cells were cultured in 
RPMI1640 with 10% HIFBS at 37° C in 5% CO2. Cells 
were passaged 3 days before experimental start and in 
log rhythmic growth phase. 2 × 106 cells were pelleted, 
washed and combined with 100uL Amaxa Nucleofector 
Solution (Lonza, Walkersville MD, USA) and then 
transferred to an Amaxa cuvette where siRNA was added 
at a concentration of 300 nM/sample. Samples were then 
electroporated using Amaxa Nucleofector Devise (Lonza, 
Walkersville MD, USA) using the M-13 protocol. After 
electroporation cells were transferred back into media and 
allowed to recover and presence of siRNA knockdown 
was detected via western blot.
Phosphoproteomic analysis
Mass spectrometry-based label-free quantitative 
phosphoproteomic profiling of the BL cell lines Raji 
and Raji4RH was performed as previously described 
[48, 49]. Briefly, six milligrams of protein from each cell 
line were digested by trypsin and peptides were subjected 
to phosphopeptide enrichment using metal oxide affinity 
chromatography (MOAC) and immunoprecipitation. An 
LTQ Orbitrap XL in-line with a Paradigm MS2 HPLC 
was employed for acquiring high-resolution MS and MS/
MS data that were searched with the Swissprot Human 
taxonomic protein database. 
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Changes in expression of PI3K/Akt target proteins 
and Bcl-2 family members by Western blot 
Following relevant drug exposure to PI3K/Akt 
inhibitors for 24 hours, cells were lysed with a RIPA 
buffer containing 2 mM PMSF, 1 μg/ml of leupeptin, 
1 μg/ml pepstatin and 1 μg/ml aprotinin. After 
solubilization at 4° C × 60 minutes, nuclei and debris 
were pelleted at 10,000 rpm for 30 minutes. Protein was 
quantified using Opsys MR (Thermo LabSystems Inc., 
Beverly, MA, USA). Lysates were prepared with equal 
amount of protein, distilled water and 4× laminar buffer. 
Lysate was loaded onto a 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gel and 
transferred onto a nitrocellulose membrane using iBLOT 
(Invitrogen Technologies, Grand Island, NY, USA). The 
membrane was blocked for a minimum of 1 hour with 
5% milk in PBS and then incubated at 4° C overnight 
with antibodies directed against proteins of interest. After 
adding the appropriate AP- or HRP-conjugated secondary 
antibody, detection was performed using enhanced 
chemiluminescence visualization system (ECL, plus, 
Amersham Life Sciences, Arlington Heights, IL, USA). 
Western blots were performed on three occasions and 
representative results are depicted.
In vitro effects of PI3K pathway inhibition on the 
viability of BL cell lines 
Cell lines were exposed to escalating doses of MK-
2206 (1–50 uM) or idelalisib (0.1–400 μM) or vehicle 
control (DMSO) for 48 hours. Cells were plated at a cell 
density of 0.25 × 106 cells/ml in 96 or 384 well plates and 
at each time period 20 μL of Alamar blue was added to 
each well and then incubated for 2 additional hours. Cell 
proliferation was determined as the change in Alamar blue 
reduction by living cells and measured using a Fluoroskan 
Ascent LF (Thermo Fisher Scientific, Barrington, IL, USA). 
In vitro effects of MK-2206 or idelalisib on the anti-
tumor activity of chemotherapy agents 
BL cells were placed in 384 well plates (1 × 105 
cells/well, cell density of 0.5 × 106 cells/ml) and exposed 
to idelalisib (1–50 uM) and/or escalating doses of cisplatin 
(0–60 μM), doxorubicin (0–10 nM), vincristine (0–1 nM) 
or dexamethasone (1–100 uM). The cells were then 
incubated at 37° C and 5% CO2 for 48 hours and changes 
in ATP levels as surrogate marker of viability, was 
measured using the CellTiter Glo luminescence assay. 
Values for exposures were normalized to vehicle treated 
control for each cell line tested.
Cell cycle progression of BL cells exposed to MK-2206 
or idelalisib 
Propidium iodide (PI) nuclear staining was utilized 
to determine the cell-cycle fractions (Sigma-Aldrich, St. 
Louis, MO, USA). Briefly, cells were exposed idelalisib 
(1, 10, 50 or 100 μM) or DMSO control for 48 hours and 
subsequently harvested, washed three times in PBS, fixed 
in 70% ethanol for 30 minutes on ice and then incubated 
in a PBS/ribonuclease solution for 30 minutes at 37° C 
(1mL PBS & 10 μM ribonuclease). Data was collected 
on a FACSCalibur flow cytometer (BD Biosciences; San 
Jose, CA, USA) and analyzed with Mod Fit LT Version 3.2 
software (Verity Software House, Topsham, ME, USA). 
Results represent the mean value of three independent 
experiments. 
Determination of apoptosis induction in BL cell lines 
exposed to MK2206 or idelalisib 
Cell lines were exposed to MK2206 or idelalisib for 
48 hours in a 6 well plate at 0.5 × 106 cells/ml. Apoptosis 
was analyzed using Western blotting (as above) using 
anti-PARP antibody and/or flow cytometry by Annexin 
V-propidium iodide staining.
Statistics
Graphic analysis was performed using IBM SPSS 
21. Significance was determined using a student’s T test. 
Synergy in combination experiments was determined 
by the Chou-Talalay method using CalcuSyn software 
and reported as Combination Index (CI) with values 
<0.9 indicating synergy and values >1.1 indicating 
antagonism.
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